Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial

被引:96
|
作者
Sikjaer, T. [1 ]
Rolighed, L. [2 ]
Hess, A. [3 ]
Fuglsang-Frederiksen, A. [3 ]
Mosekilde, L. [1 ]
Rejnmark, L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, MEA, Osteoporosis Clin, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Neurophysiol, DK-8000 Aarhus, Denmark
关键词
Hypoparathyroidism; Muscle function; Quality of life; rhPTH(1-84); PARATHYROID-HORMONE; 1-34; HYPOCALCEMIC MYOPATHY; IDIOPATHIC HYPOPARATHYROIDISM; AMPLITUDE; STRENGTH; BALANCE; GO;
D O I
10.1007/s00198-014-2677-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of treatment with 100 mu g parathyroid hormone (PTH) (1-84) or an identical placebo on muscle function and quality of life (QoL) was studied in hypoparathyroid patients. At baseline, we found reduced QoL but no myopathy in the patients. Six months of treatment did not improve QoL, and muscle strength decreased slightly. A reduced quality of life (QoL) and myopathy that may be due to the absence of PTH have been reported in patients with hypoparathyroidism (hypoPT). Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 mu g/d s.c. or placebo, given as add-on therapy to conventional treatment. Muscle function and postural stability were investigated using a dynamometer chair, a stadiometer platform, the repeated chair stands test, the timed up and go test, and electromyography. QoL was assessed using the 36-item Short Form Health Survey and the WHO-5 Well-Being Index. The mean age of the patients was 52 +/- 11 years, and 85 % were females. At baseline, QoL was significantly reduced in comparison with norm-based scores. Compared with placebo, PTH did not improve QoL or muscle function. Rather, max force production decreased significantly by 30 % at elbow flexion in the PTH group compared with the placebo group. Moreover, there was a nonsignificant trend for muscle strength to decrease in the upper extremities and on knee extension in response to PTH. Treatment did not affect postural stability. Electromyography showed a slight decrease in the duration of motor unit potentials in the PTH group, indicating a tendency toward myopathy, which, however was not symptomatic. Overall, our data do not support an immediate beneficial effect of PTH replacement therapy on muscle function or QoL. A high frequency of hypercalcemia among our patients may have compromised the potential beneficial effects of reversing the state of PTH insufficiency.
引用
收藏
页码:1717 / 1726
页数:10
相关论文
共 50 条
  • [1] Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial
    T. Sikjaer
    L. Rolighed
    A. Hess
    A. Fuglsang-Frederiksen
    L. Mosekilde
    L. Rejnmark
    [J]. Osteoporosis International, 2014, 25 : 1717 - 1726
  • [2] PTH(1-84) substitution therapy in hypoparathyroidism: Effects on muscle cells and muscle function
    Sikjaer, T.
    Rolighed, L.
    Rejnmark, L.
    Mosekilde, L.
    [J]. BONE, 2012, 50 : S177 - S177
  • [3] The Effect of PTH(1-84) on Quality of Life in Hypoparathyroidism
    Cusano, Natalie E.
    Rubin, Mishaela R.
    McMahon, Donald J.
    Irani, Dinaz
    Tulley, Amanda
    Sliney, James, Jr.
    Bilezikian, John P.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (06): : 2356 - 2361
  • [4] PTH(1-84) Replacement Therapy in Hypoparathyroidism: A Randomized Controlled Trial on Pharmacokinetic and Dynamic Effects After 6 Months of Treatment
    Sikjaer, Tanja
    Amstrup, Anne Kristine
    Rolighed, Lars
    Kjaer, Soren Geill
    Mosekilde, Leif
    Rejnmark, Lars
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (10) : 2232 - 2243
  • [5] PTH(1-84) REPLACEMENT THERAPY IN HYPOPARATHYROIDISM (HYPOPT): A RANDOMIZED CONTROLLED TRIAL ON PHARMACOKINETICS AND DYNAMIC EFFECTS FOLLOWING 24 WEEKS OF TREATMENT
    Sikjaer, Tanja
    Rolighed, Lars
    Amstrup, Anne Kristine
    Rejnmark, Lars
    Mosekilde, Leif
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S352 - S352
  • [6] PTH(1-84) replacement therapy for the treatment of hypoparathyroidism
    Cusano, Natalie E.
    Rubin, Mishaela R.
    Bilezikian, John P.
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (01) : 5 - 13
  • [7] PTH(1-84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy
    Cusano, Natalie E.
    Rubin, Mishaela R.
    McMahon, Donald J.
    Irani, Dinaz
    Anderson, Laura
    Levy, Elizabeth
    Bilezikian, John P.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10): : 3694 - 3699
  • [8] PTH(1-84) Is Associated with Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy
    Cusano, Natalie
    Rubin, Mishaela
    McMahon, Donald
    Irani, Dinaz
    Anderson, Laura Beth
    Levy, Elizabeth
    Bilezikian, John
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S356 - S356
  • [9] Effects of add on PTH(1-84) substitution therapy in hypoparathyroidism: Results from a double-blind randomised controlled study
    Sikjaer, T. T.
    Rejnmark, L.
    Mosekilde, L.
    [J]. BONE, 2011, 48 : S83 - S83
  • [10] PTH (1-84) REPLACEMENT THERAPY IN HYPOPARATHYROIDISM: EFFECTS ON BONE METABOLISM AND STRUCTURE
    Sikjaer, Tanja
    Rejnmark, Lars
    Thomsen, Jesper S.
    Bruel, Annemarie
    Mosekilde, Leif
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S255 - S256